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Dual Antiplatelet Therapy After
Coronary Stenting
Looking at the Speck Rather Than Noticing the Log?*Giuseppe Biondi-Zoccai, MD,y Giacomo Frati, MD,yz Antonio Abbate, MD, PHDx“Why do you look at the speck that is in
your brother’s eye, but do not notice
the log that is in your own eye?”
—Matthew 7:3 (1)A distinctive feature of interventional cardiolo-gists relies in the fact that they take care ofpatients well before and after the invasive
procedures. This explains why the most appropriate
medical management following percutaneous coro-
nary intervention (PCI) remains a key issue for
interventionalists.
History reminds us that the ﬁrst stents (Wallstent
and Palmaz-Schatz) were plagued by an almost
unethically high short-term risk of thrombosis. Anto-
nio Colombo’s breakthrough with dual antiplatelet
therapy (DAPT) ushered a new era for stenting, shift-
ing the focus from thrombosis to restenosis. Yet,
the advent of drug-eluting stents (DES) more than
10 years ago brought again a wave of uncertainty on
the safety of PCI, and in 2006 the European Society
of Cardiology Congress highlighted the potentially
deadly hazard associated with DES (2).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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what was decided and recommended by many ex-
perts in 2007: routine DAPT for at least 12 months in
everybody receiving a DES (3). Indeed, a simple
Google Scholar search for “dual antiplatelet therapy
discontinuation” shows the 2 most cited articles are
this guideline itself and a 4-patient case series (3,4).
This is keeping with the lack, until recently, of any
randomized trial focusing on this issue.
Some more robust evidence on DAPT has been
published recently (5), and further insights will be
provided by their synthesis with pairwise and network
meta-analyses (6,7). On one hand, the 12-month dogma
has been challenged and shorter-term regimens envi-
sioned. Yet, the DAPT (Dual Antiplatelet Therapy)
study has highlighted that a 30-month regimen may
reduce thrombotic events, albeit at the possible
expense of an increase in apparently non-
cardiovascular death (5). The scenario on the most
appropriate antithrombotic management after coro-
nary stenting is also compounded by the large evi-
dence base suggesting that premature cessation of
DAPT is prognostically unfavorable (8,9). There is,
however, a problem with terminology because
different types of cessation can occur (Table 1).SEE PAGE 404This issue of JACC: Cardiovascular Interventions
provides incremental data with the EDUCATE registry
(10). This 2,265-patient prospective observational
study focused on nonadherence to DAPT after PCI
(originally prescribed for 12 months). Nonadherence
was deﬁned as missing $1 day of DAPT, whereas se-
vere nonadherence was deﬁned as missing $2 weeks.
After 6 months, nonadherence occurred in 9.6%
TABLE 1 Type, Subtype, Incidence, and Consequence of Suboptimal DAPT
After Coronary Stenting
Type Subtype Deﬁnition Incidence
Prognostic
Impact
Underuse Not established Act of using (or prescribing) less
than expected
þ þ
Noncompliance Not established Inaccuracy with which a patient
follows an agreed treatment
plan
þ þ
Cessation Interruption Physician-supervised
temporary cessation
þþ þ/
Discontinuation Physician-supervised
permanent cessation
þþ þ/
Disruption Cessation due to noncompliance
or actual bleeding
þ þþ
þþ ¼ high/strong; þ ¼ moderate; þ/ ¼ low/mild; DAPT ¼ dual antiplatelet therapy.
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412and severe nonadherence in 5.2%, and the only
independent predictor of nonadherence was major
bleeding. Nonadherence up to 6 months was associ-
ated, even at multivariable analysis, with an in-
creased 12-month risk of death/myocardial infarction
(odds ratio: 1.95 [95% conﬁdence interval: 1.02 to
3.75], p ¼ 0.045). Notably, nonadherence up to
3 months or between 3 and 6 months were similarly
detrimental, whereas nonadherence after 6 months
did not appear impactful.
What are the key strengths of this work? First, the
relatively large size and ensuing statistical precision.
Second, the prospective design and reliance on a
single DES, thus increasing precision. Third, the
participation of institutions with state-of-the-art fa-
cilities and expertise.
Yet, some drawbacks may be highlighted. First,
there is no detailed analysis on the type and subtype
of nonadherence. In particular, it has been shown
that disruption is the most ominous variant of non-
adherence, whereas other subtypes are more benign
(9). Second, this work misses the opportunity to unifythe many elements underpinning decision making on
DAPT by simultaneously and appropriately weighing
beneﬁts and risks. Third, the focus on phosphoryl-
coated zotarolimus-eluting stents partly undermines
the importance of the report because this stent is
considered rather obsolete in many settings, given its
suboptimal antirestenotic effect (11). Fourth, lumping
together short-term nonadherence and longer epi-
sodes of nonadherence appears superﬁcial, because
brief cessations may be rather safe (8,12). Fifth, the
large conﬁdence intervals and the marginally signiﬁ-
cant p value do not prove strictly convincing and
could hint at residual confounding. Sixth, the focus
on a 6-month threshold has been already challenged,
especially when using DES with a superior safety
proﬁle (6). Seventh, there was no chance in this study
to test or appraise means to minimize noncompliance
or cessation. Although some approaches (such as the
Interactive Monitoring Service, FBCommunication,
Modena, Italy) have been advocated, the evidence
base on them is still scant, and even observational
perspectives could be useful.
In conclusion, underuse, noncompliance, and
cessation of evidence-based antithrombotic therapies
remain important and potentially hazardous for pa-
tients undergoing PCI with DES. More focus is, how-
ever, needed also on the subtleties of this clinical
conundrum, including treatment individualization
for drug type, dosage, duration, and combination.
Otherwise, we may risk unduly looking at the speck
rather than at the log of safe, effective, appropriate,
and affordable cardiovascular care.
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